| Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’study HJN Andreyev, AR Norman, D Cunningham, J Oates, BR Dix, ... British journal of cancer 85 (5), 692-696, 2001 | 1080 | 2001 |
| STAT proteins: from normal control of cellular events to tumorigenesis V Calò, M Migliavacca, V Bazan, M Macaluso, M Buscemi, N Gebbia, ... Journal of cellular physiology 197 (2), 157-168, 2003 | 840 | 2003 |
| The TP53 Colorectal Cancer International Collaborative Study on the Prognostic and Predictive Significance of p53 Mutation: Influence of Tumor Site, Type of … A Russo, V Bazan, B Iacopetta, D Kerr, T Soussi, N Gebbia Journal of clinical oncology 23 (30), 7518-7528, 2005 | 516 | 2005 |
| Founder mutations in BRCA1 and BRCA2 genes R Ferla, V Calo, S Cascio, G Rinaldi, G Badalamenti, I Carreca, ... Annals of Oncology 18, vi93-vi98, 2007 | 403 | 2007 |
| Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype V Bazan, M Migliavacca, I Zanna, C Tubiolo, N Grassi, MA Latteri, ... Annals of Oncology 13 (9), 1438-1446, 2002 | 304 | 2002 |
| miR‐20b modulates VEGF expression by targeting HIF‐1α and STAT3 in MCF‐7 breast cancer cells S Cascio, A D'Andrea, R Ferla, E Surmacz, E Gulotta, V Amodeo, V Bazan, ... Journal of cellular physiology 224 (1), 242-249, 2010 | 267 | 2010 |
| Male breast cancer L Ottini, D Palli, S Rizzo, M Federico, V Bazan, A Russo Critical reviews in oncology/hematology 73 (2), 141-155, 2010 | 263 | 2010 |
| Ras family genes: an interesting link between cell cycle and cancer M Macaluso, G Russo, C Cinti, V Bazan, N Gebbia, A Russo Journal of cellular physiology 192 (2), 125-130, 2002 | 241 | 2002 |
| Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? G Badalamenti, D Fanale, L Incorvaia, N Barraco, A Listi, R Maragliano, ... Cellular immunology 343, 103753, 2019 | 219 | 2019 |
| Hereditary ovarian cancer A Russo, V Calò, L Bruno, S Rizzo, V Bazan, G Di Fede Critical reviews in oncology/hematology 69 (1), 28-44, 2009 | 194 | 2009 |
| Patterns of genomic instability in gastric cancer: clinical implications and perspectives L Ottini, M Falchetti, R Lupi, P Rizzolo, V Agnese, G Colucci, V Bazan, ... Annals of Oncology 17, vii97-vii102, 2006 | 184 | 2006 |
| Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma G Bronte, S Rizzo, L La Paglia, V Adamo, S Siragusa, C Ficorella, ... Cancer treatment reviews 36, S21-S29, 2010 | 173 | 2010 |
| PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis F Passiglia, G Bronte, V Bazan, C Natoli, S Rizzo, A Galvano, A Listì, ... Oncotarget 7 (15), 19738, 2016 | 169 | 2016 |
| Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia … V Bazan, V Agnese, S Corsale, V Calo, MR Valerio, MA Latteri, S Vieni, ... Annals of oncology 16, iv50-iv55, 2005 | 169 | 2005 |
| Circular RNA in exosomes D Fanale, S Taverna, A Russo, V Bazan Circular RNAs: biogenesis and functions, 109-117, 2018 | 165 | 2018 |
| Potential role of ANGPTL4 in the cross talk between metabolism and cancer through PPAR signaling pathway L La Paglia, A Listì, S Caruso, V Amodeo, F Passiglia, V Bazan, D Fanale PPAR research 2017, 2017 | 158 | 2017 |
| Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study B Iacopetta, A Russo, V Bazan, G Dardanoni, N Gebbia, T Soussi, D Kerr, ... Annals of oncology 17 (5), 842-847, 2006 | 154 | 2006 |
| The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies LR Corsini, G Bronte, M Terrasi, V Amodeo, D Fanale, E Fiorentino, ... Expert opinion on therapeutic targets 16 (sup2), S103-S109, 2012 | 147 | 2012 |
| Breast cancer genome-wide association studies: there is strength in numbers D Fanale, V Amodeo, LR Corsini, S Rizzo, V Bazan, A Russo Oncogene 31 (17), 2121-2128, 2012 | 146 | 2012 |
| Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? S Rizzo, G Bronte, D Fanale, L Corsini, N Silvestris, D Santini, G Gulotta, ... Cancer treatment reviews 36, S56-S61, 2010 | 136 | 2010 |
